| Advisory Board and Contents | 2022/07/01 | English | |
| Challenges and opportunities for physician-scientists in advancing cancer research | 2022/08/01 | English | |
| Making a mouse out of a molehill: how precision modeling repurposes drugs for congenital giant nevi | 2022/08/01 | English | |
| Subscription & copyright page | 2022/11/01 | English | |
| Advisory Board and Contents | 2022/11/01 | English | |
| Advisory Board and Contents | 2022/12/01 | English | |
| Subscription & copyright page | 2022/12/01 | English | |
| Ancestry-defined molecular taxonomy of prostate cancer | 2022/12/01 | English | |
| Making normal hematopoiesis invisible to CAR T cells | 2023/12/01 | English | |
| Updating cancer research with patient-focused networks | 2024/01/01 | English | |
| Taking the STING out of CIN | 2023/12/01 | English | |
| Subscription & copyright page | 2023/11/01 | English | |
| Targeting TEAD-ious resistance | 2023/10/01 | English | |
| Digging deeper into the early steps of cancer progression | 2023/09/01 | English | |
| Advisory Board and Contents | 2023/08/01 | English | |
| Subscription & copyright page | 2023/08/01 | English | |
| CD4+ T cells help myeloid-mediated killing of immune-evasive tumors | 2023/10/01 | English | |
| Single-cell characterization of tumor evolution from precursor diseases | 2023/10/01 | English | |
| Subscription & copyright page | 2022/05/01 | English | |
| Advisory Board and Contents | 2022/05/01 | English | |
| Advisory Board and Contents | 2022/06/01 | English | |
| Subscription and copyright page | 2022/06/01 | English | |
| Subscription & copyright page | 2023/01/01 | English | |
| Advisory Board and Contents | 2023/01/01 | English | |
| The development of therapy related myeloid neoplasms in childhood cancer survivors | 2022/10/01 | English | |
| Advisory Board and Contents | 2022/08/01 | English | |
| Subscription and copyright page | 2022/08/01 | English | |
| Advisory Board and Contents | 2023/12/01 | English | |
| Subscription & copyright page | 2023/12/01 | English | |
| Advisory Board and Contents | 2023/05/01 | English | |